1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington. 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
1UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland. 2Systems Biology Ireland, UCD School of Medicine, University College Dublin, ...
1Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Elizabeth J. Schafer, Surveillance ...
*Corresponding Author: Anne McTiernan, Public Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Avenue North, P.O. Box 19024, Seattle, WA 98109. E-mail: [email protected] ...
Abstract. We investigated the effect of small molecules extracted from the latex of Calotropis procera (CPPE) to act as inhibitors of Heat Shock Protein 90 (HSP90), a key molecular chaperone co-opted ...
Cellentia Inc., Foster City, CA. Search for other works by this author on: ...
Search for other works by this author on: ...
Search for other works by this author on: ...
Suzhou Genhouse Pharmaceutical Co., Ltd., Suzhou, China.
Dana-Farber Cancer Institute, Boston, MA.
University of Chicago, Chicago, IL.
PDL1V is a novel vedotin antibody drug-conjugate (ADC) currently in Phase I clinical development for advanced solid tumors as a monotherapy or in combination with pembrolizumab (NCT05208762). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback